Latest Conference Articles

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

Philip Mease, MD, discusses the different treatment options now available for patients with psoriasis and psoriatic arthritis.

Jerry Shapiro, MD, discusses strategies for treating patients with scarring and nonscarring alopecia.

Experts discuss groundbreaking therapies in dermatology at Maui Derm 2026, addressing complex skin diseases and enhancing patient care with innovative treatments.

Paul Nghiem, MD, PhD, discusses individualized therapies and the evolving role of AI in improving outcomes for actinic keratosis and related skin conditions.

Lawrence Eichenfield, MD, outlines a patient-centered approach to atopic dermatitis, assessing disease history, life impact, and prior therapy use.

Daniel Siegel, MD, discusses a loophole he looks out for in ICD-10 coding and billing.

Maui Derm 2026 showcases groundbreaking clinical trial data and innovative strategies in dermatology.

Alongside physician collaboration, patient advocacy is essential to ensure clinical trials and public policy reflect patient-centered outcomes.

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard care for aggressive HER2-driven gastrointestinal cancers.

Presenters shared their personal highlights of attending ASCO GI 2026.

Patient–physician collaboration ensures trials reflect outcomes that matter to patients, according to Debra Patt, MD, PhD, MBA, MPH.

Dani Castillo, MD, sheds light on the evolving landscape of first-line therapy in advanced gastric cancer.

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

Yara Abdou, MD, emphasizes that addressing fertility, survivorship, and quality of life is key to improving outcomes for young patients with breast cancer.

Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver metastases.

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal approaches.

The complex disparities in pancreatic cancer survival trends across demographics and regions highlight urgent needs for targeted interventions.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

Tobacco use significantly impacts gastric and esophageal cancer outcomes, highlighting the need for targeted public health strategies and smoking cessation efforts.

Enrique Velazquez Villarreal, MD, PhD, MPH, MS, reveals how AI is being used to identify early-onset CRC and enhance precision oncology.

The trial is investigating zanidatamab with/without tislelizumab plus chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma.

Genetic and metabolic differences may increase aggressive early breast cancer risk in Latin American women with obesity, notes William Audeh, MD, MS.

Smart pill bottles may boost adherence to oral breast cancer therapies through daily reminders and tracking, though cost and technology barriers remain, says Steven Manobianco, MD.